Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JPMorgan resumes coverage of Glencore at 'overweight'

(Sharecast News) - JPMorgan Cazenove resumed coverage of Glencore on Tuesday with an 'overweight' rating and 360p price target following a two-year period of restriction relating to Viterra's merger with Bunge Global. The bank said "optionality" is a central theme for its positive outlook on the miner.

It noted that Glencore has lagged the MSCI Europe by 45% since May 2024 due to weak operating results and more than 25% lower coal prices.

JPM said group production will significantly step up in H2'25 led by copper, which it forecasts will translate into around 150% higher group earnings in 2026, 250% higher in 2027 versus 2025.

"GLEN is returning circa 6% of its market cap in 2025 and we estimate circa 7%/20% excess capital by YE'26/27 if commodity prices increase 10%," the bank said.

"On a more than 12 month horizon, spot coal prices may carry upside risk since about 60% of global energy coal supply is cash loss making at current prices, circa 30% for steelmaking coal," it said.

JPM said Glencore possesses "value-accretive strategic optionality". The bank said it had explored equity and credit considerations relating to a hypothetical Coal de-merger and estimates this could be a comfortable catalyst for a circa 15-20% re-rating for Glencore to 350p to 370p a share.

At 1310 BST, the shares were up 2.8% at 306.10p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.